School of Medicine
Showing 1-2 of 2 Results
Peter Johannes van Roessel
Clinical Associate Professor, Psychiatry and Behavioral Sciences
Bio Dr Peter van Roessel, M.D. Ph.D, completed his MD at Stanford University and his residency training in psychiatry at Columbia University and the New York-Presbyterian Hospital in New York City. Prior to joining the clinical faculty at Stanford, he worked for several years as Associate Director of the general research unit of the New York State Psychiatric Institute, a premier state-funded research hospital affiliated with Columbia University, where he provided clinical care for individuals participating in research studies across a spectrum of psychiatric illness, including treatment resistant mood disorders, anxiety disorders, psychosis and substance use disorders.
At Stanford, he sees adult mood and anxiety disorders outpatients through the Evaluations Clinic and Depression Clinic and participates in resident training and patient care as a supervisor in psychodynamic psychotherapy and as an attending physician in Continuity Clinic. As a member of the department's Rodriguez Translational Therapeutics Lab, he sees individuals with obsessive-compulsive spectrum disorders for evaluations and research-protocol driven clinical treatment, and contributes to clinical neuroscience studies pioneering rapid-acting interventions in OCD.
Dr van Roessel pursued research training basic neuroscience prior to his clinical training, completing an MPhil in Biology via the Open University, UK, for research performed at the Max Planck Institute for Developmental Biology in Tübingen Germany, and a PhD in molecular and developmental neurobiology in the laboratory of Dr Andrea Brand at the University of Cambridge, UK. More recently, he has contributed to work in the lab of Dr Julia Kaltschmidt (Sloan Kettering Institute, now Stanford) on studies of GABAergic/Glutamatergic interneuronal circuity in mouse. In the Rodriguez Lab, he is pursuing clinically-motivated research interests related to the nature and neural correlates of insight in obsessive-compulsive and related disorders. He has additionally received a 2018 NARSAD Young Investigator Award to pursue a novel glutamatergic rapid-acting treatment for OCD.